Trial Profile
Open label Phase I Study of Everolimus(RAD001) plus Doxorubicin in advanced progressive and refractory thyroid cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 19 Sep 2017
Price :
$35
*
At a glance
- Drugs Everolimus (Primary) ; Doxorubicin
- Indications Thyroid cancer
- Focus Adverse reactions
- Acronyms THYRADOX
- 11 Sep 2017 Status changed from recruiting to completed.
- 29 Aug 2011 New trial record